Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His addition is expected to support Arcutis' strategy to grow its ZORYVE franchise and expand its pipeline in immuno-dermatology. Peetz currently leads Mirum Pharmaceuticals and has a strong background in finance and corporate development within the biotech sector.
T3 Defense Inc. will execute a 1-for-125 reverse stock split on July 20, 2026, combining every 125 shares into one to increase its share price. This move aims to raise the stock price from its current low of $0.05 per share and comply with NASDAQ lis...
General Electric, now operating as GE Aerospace, reported strong Q2 2026 earnings with EPS of $2.02 and revenue of $13.35 billion, both exceeding analyst expectations. The company's growth was driven by high demand in its commercial aerospace service...
Heilind Electronics announced the availability of the Brady i4311 Industrial Label Printer, a portable, cordless printer that combines benchtop-quality wide-format printing with all-day battery life and ergonomic design. Weighing 13 lbs and capable o...
The American Kidney Fund (AKF) has launched a new online course on lupus nephritis through its Kidney Health Coach program. This initiative aims to educate both community members and healthcare professionals about the symptoms, testing, diagnosis, tr...
UnitedHealth Group reported strong Q2 earnings per share of $6.38, surpassing analyst estimates of around $4.90. Revenue also exceeded expectations at $112.03 billion, showing continued growth from last year. Following the results, the company raised...
